Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that its lead product candidate, NRTX-1001, ...

For the millions of people worldwide living with severe forms of epilepsy, some do not respond to medication and it can be ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among those deemed “treatment sensitive,” 69.4% ...

Patients with treatment-resistant epilepsy often cycle through multiple medications as they seek relief from the seizures ...

Please provide your email address to receive an email when new articles are posted on . Researchers examined data of 40 adults with focal epilepsy. Patients from disadvantaged neighbhorhoods tended to ...

Focal treatment-resistant epilepsy improves over time, but seizure reduction appears to be unrelated to specific medications ...

Early detection of focal epilepsy may reduce the amount of motor vehicle accidents caused by seizures while driving. The prevalence of seizures while driving (SzWD) prior to diagnosis in people with ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they too may eventually see improvement, if not ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Implantation of so-called inhibitory neurons helped ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to study BHV-7000, a novel investigational therapy, in focal epilepsy.

NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be presented ...